Literature DB >> 7584100

Cultured human myoblasts and myotubes show markedly different transducibility by replication-defective adenovirus recombinants.

G Acsadi1, A Jani, J Huard, K Blaschuk, B Massie, P Holland, H Lochmüller, G Karpati.   

Abstract

Human adenovirus (AV) is a favored vector for delivery of therapeutic genes into certain target cells, such as skeletal muscle cells for gene therapy. Here we show that replication-defective (E1 + E3 deleted) human type 5 adenovirus (AV) recombinants containing a reporter gene insert (RSV-luciferase or RSV-Lux) can very efficiently transduce cultured human myoblasts. However, transduction efficiency is about one order of magnitude less in cultured myotubes 16 days postfusion. The high transduction of myoblasts by AV-RSV-Lux could be effectively blocked by an arginine-glycine-asparagine (RGD) oligopeptide that serves as a ligand for the natural internalization receptor of AV. The normalized level of beta 3/beta 5-integrin, the main component of the internalization receptor for AV is about three times as abundant in myoblasts than in myotubes. This could contribute, among other things, to the relatively high susceptibility of myoblasts to AV infection and AV-mediated gene transduction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7584100

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  11 in total

1.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

Review 2.  Nonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disorders.

Authors:  Pedro R Lowenstein; Donata Suwelack; Jinwei Hu; Xianpeng Yuan; Maximiliano Jimenez-Dalmaroni; Shyam Goverdhana; Maria G Castro
Journal:  Int Rev Neurobiol       Date:  2003       Impact factor: 3.230

3.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers.

Authors:  J Huard; W G Feero; S C Watkins; E P Hoffman; D J Rosenblatt; J C Glorioso
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 5.  Adenovirus-mediated gene transfer into striated muscles.

Authors:  G Acsadi; B Massie; A Jani
Journal:  J Mol Med (Berl)       Date:  1995-04       Impact factor: 4.599

6.  Genomic integration of adenoviral gene transfer vectors following transduction of fertilized mouse oocytes.

Authors:  Nancy Larochelle; Rolf Stucka; Norman Rieger; Lothar Schermelleh; Gudrun Schiedner; Stefan Kochanek; Eckhard Wolf; Hanns Lochmüller
Journal:  Transgenic Res       Date:  2010-05-13       Impact factor: 2.788

Review 7.  Progress in gene therapy for Duchenne muscular dystrophy.

Authors:  P R Clemens; F J Duncan
Journal:  Curr Neurol Neurosci Rep       Date:  2001-01       Impact factor: 5.081

8.  Muscle-specific overexpression of the adenovirus primary receptor CAR overcomes low efficiency of gene transfer to mature skeletal muscle.

Authors:  J Nalbantoglu; N Larochelle; E Wolf; G Karpati; H Lochmuller; P C Holland
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

9.  Development of approaches to improve cell survival in myoblast transfer therapy.

Authors:  Z Qu; L Balkir; J C van Deutekom; P D Robbins; R Pruchnic; J Huard
Journal:  J Cell Biol       Date:  1998-09-07       Impact factor: 10.539

10.  Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid.

Authors:  Christoph Volpers; Christian Thirion; Volker Biermann; Stefanie Hussmann; Helmut Kewes; Patrick Dunant; Helga von der Mark; Andreas Herrmann; Stefan Kochanek; Hanns Lochmüller
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.